Using Afrezza inhaled insulin with a CGM
November 3, 2014- Interviewed by Steven E. Greer, MD
Inhaled insulin will make a comeback when Mannkind’s drug, Afrezza, goes on sale in early 2015. It will be marketed by Sanofi.
We interviewed the CEO of Dexcom, Terry Gregg, about how a CGM can play a role in this new therapeutic category. Type-1 diabetes expert, Jay Skyler, MD, also explains the clinic role of CGM with a super-rapid-acting prandial insulin.
Diabetes, FDA, Medical Devices, Pediatrics, Univ Miami | apples49 | 
January 15, 2015 2:07 pm
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
